PMCB (PharmaCyte Biotech) Float Percentage Of Total Shares Outstanding : 57.96% (As of Dec. 15, 2024)

View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PharmaCyte Biotech's float shares is 4.45 Mil. PharmaCyte Biotech's total shares outstanding is 7.68 Mil. PharmaCyte Biotech's float percentage of total shares outstanding is 57.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PharmaCyte Biotech's Insider Ownership is 8.39%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PharmaCyte Biotech's Institutional Ownership is 10.93%.

PharmaCyte Biotech Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

PharmaCyte Biotech's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	4.45	/	7.68
	=	57.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website

https://pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb	director	100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen	director	299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K	director
Carlos Trujillo	director, officer: CFO	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner	director, officer: Chairman, CEO, Pres and GC	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree	director, officer: Chief Science Officer	12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099